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Nowadays, in the postgenome time, many “-ome” studies have emerged including proteome, transcriptome, interactome, me-
tabolome, adipokinome, connectome. In this vein, the catchall term NGF-ome embodies all the actions of NGF in health and 
disease. Accordingly, the present Festschrift, also tabula gratulatoria, is to honor and acknowledge the contributions of the 
distinguished neuroscientist and magistra Rita Levi-Montalcini, the Nobel Prize winner-1986 for the discoverer of NGF. Today, 
NGF and another neurotrophin, brain-derived neuroptrophic factor (BDNF), are well recognized to mediate multiple biologi-
cal phenomena, ranging from the neurotrophic through immunotrophic and epitheliotrophic to metabotrophic effects. These 
latter effects are involved in the maintenance of cardiometabolic homeostasis (glucose and lipid metabolism as well as energy 
balance, and cardioprotection). Circulating and/or tissue levels of NGF and BDNF are altered in cardiometabolic diseases 
(atherosclerosis, obesity, type 2 diabetes, metabolic syndrome, and type 3 diabetes/Alzheimer’s disease). A hypothesis thus 
emerged that a metabotrophic deficit due to the reduction of NGF/BDNF availability and/or utilization may be implicated in the 
pathogenesis of cariometabolic and neurodegenerative diseases. The present challenge is therefore to cul tivate a metabotrophic 
thinking about how we can modulate NGF/BDNF secretion and signaling for the benefit of human cardiometabolic and mood 
health. Biomed Rev 2010; 21: 25-29.
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INTRODUCTION
 “Ome sweet ome”
 Initial part of the title of article by Lichtman JW 
 and Sanes JR published in
 Curr Opin Neurobiol 2008;18:346-353.
Recent studies provide evidence that morbid obesity is a ma-
jor burden of human health that plays a pivotal role in the 
development of cardiometabolic diseases (CMD) (Table 1), 
also non-alcoholic steatohepatitis, obstructive sleep apnea 
syndrome, polycystic ovary syndrome, and Alzheimer’s dis-
ease. These are among the major health, social and economic 
evils of Homo sapiens recens, globally. The World Health 
Organization has predicted a “globesity epidemic” with more 
than one billion adults being overweight (BMI over 25 kg/
m2) and at least 400 million of these being clinically obese 
(BMI over 30 kg/m2). Moreover, CMD are associated with 
cognitive and mood disorders including Alzheimer’s disease 
and depression (1-8). Arguably, we have learned more about 
the molecular control of food intake and energy homeostasis, 
particularly, the role played by adipose tissue in the patho-
genesis of various diseases, including CMD. Cumulatively, 
such an adipocentric approach (8-13) has integrated the tradi-
tional cardovascular risks (age, sex, smoking, hypertension, 
dyslipidemia, homocysteinemia) and abdominal obesity and 
related features of the metabolic syndrome, hence, global 
cardiometabolic risk (14-16, cf. 17-19). 
IMPLICATION OF NGF AND BDNF IN CARDIOMETABOLIC 
DISEASE: RESULTS OF A DREAM
During his student life at the Medical University, Varna, Bul-
garia, one of us (GNC) used to work four years (1962-1966) 
as research associated at the Department of Pharmacology. It 
was that period of time when he for the first time “met” Pro-
fessor Rita Levi-Montalcini, reading her first papers on nerve 
growth factor (NGF). Since then he has being infected by 
this talented molecule, and thought how to reach her Institute 
in Rome, Italy. Although some colleagues told him that it is 
very much difficult pursuit, he continued to believe more in 
the art of dream as presented by Emily Dickinson’s To Make 
a Prairie (To make a prairie it takes a clover and one bee,/ 
One clover, and a bee,/And revery./ The dream alone will do,/ 
If bees are few.)
Although in 1986-1987 (in Japan) as well as in 1991-1992 
(in England) he liked to study the effect of NGF on vascular 
smooth muscle cells in culture and the expression of NGF in 
perivascular mast cells knowing Aloe and Montalcini publi-
cation (20), the host scientists have ignored his hypotheses. 
But not his dream! On its road, he, in 1995 contacted Luigi 
Aloe and invited him to contribute to Biomedical Reviews. In 
1997 he has applied for NATO Research Fellowship, which 
required acceptance letter by the host institution. Obviously, 
his dream asked Luigi Aloe about and he provided him with 
such a letter, consequently awarded a fellowship allowing 
him appeared in the Institute of Neurobiology, CNR, Rome, 
in June 1998. During this first four months there as well as 
almost each year further on, he was honored of meeting in 
vivo many times Rita Levi-Montalcini. 
NGF-OME PROJECT
At the beginning of this century the Human Genome Project 
was finalized estimating over 30 000 genes encoding more 
than 100 000 functionally distinct proteins. As happened 
usually, one solved problem delivered many unsolved ones. 
Thus in the postgenome time, many “-ome” projects have 
emerged including proteome, transcriptome, interactome, 
metabolome, adipokinome, connectome. In this vein, all the 
actions of NGF in health and disease are herein referred to 
as NGF-ome. 
Since 1951 when the NGF was discovered followed by 
the discovery of other neurotrophins including brain-derived 
neurotrophic factor (BDNF) (Table 2), it has been increas-
ingly recognized that life at neuronal level requires trophic 
support (21-26). 
As often occurs, the framework of an initial conception 
of the role of a newly discovered biomolecule extends in the 
light of emerging findings. This was also the case for NGF. 
During some 25 years after its discovery, there have been few 
reasons given to indicate that NGF acts on nonneuronal cells. 






Type 2 diabetes mellitus
Metabolic syndrome
Metabolic-cognitive syndrome (2)
Type 3 diabetes mellitus (1,3-5)*
* For references for other diseases, see the text. 
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Table 3. NGF and BDNF as metabotrophins
NGF shares homology with proinsulin
NGF/BDNF are produced by pancreatic beta cells and 
exert insulinotropic effect
NGF/BDNF are trophic factors for pancreatic beta cells, 
also improve beta cell transplantation
NGF up-regulates expression of LDL receptor-related 
protein
NGF inhibits glucose-induced down-regulation of ca-
veolin-1
NGF improves antioxidant homeostasis
NGF/BDNF decrease food intake 
NGF supplementation rescues silent myocardial 
ischemia in diabetes mellitus
Healthy lifestyle increases brain and/or circulating lev-
els of NGF/BDNF
Atherogenic risk factors (e.g., high fat diet) decrease 
NGF/BDNF levels
NGF improves diabetic erectile dysfunction
Circulating NGF levels are increased in the early stage 
of romantic love
* For the implication of NGF in nerve sprouting in sudden 
cardiac death, see 50,51. References for other items are 
listed in 8,9.






Neurotrophin (NT-3, NT 4/5, NT-6, NT-7)
* Two peptides derived from the pro-NGF: LIP1 is a 29-ami-
no acid peptide, LIP2 is a 38-amino acid peptide, both cor-
responding to sequences within the NGF (47-49). 
Thus, in 1975, Aloe and Levi-Montalcini have made an ex-
periment demonstrating that treatment of newborn rats with 
NGF caused an increase in the number of mast cells in vari-
ous organs. These findings (20) have triggered the study on 
neuroimmune interaction, leading to today’s accumulation of 
evidence that NGF is not only for neuronal life. Indeed, “the 
submerged areas of the NGF iceberg loom very large”, Rita 
Levi-Montalcini stated in her Nobel prize lecture reviewing 
35 years of research on NGF (22). 
Cumulatively, studies in the past three decades have re-
vealed that the neurotrophins NGF and BDNF are not only 
stimulating for nerve growth and survival, but also exert 
trophic effects over (i) immune cells, acting as immuno-
trophins (20,27), (ii) keratinocytes, enterocytes, prostate and 
breast epithelial cells, acting as epitheliotrophins (see 21), 
(iii) endothelial cells, acting as angiogenic factors (28), and 
(iv) glucose, lipid and energy homeostasis, pancreatic beta 
cell and vascular system as well as wound healing, and thus 
designated metabotrophins (from Greek metabole and tro-
phe, nutrition, means “nutritious for metabolism”) (8,18). 
METABOTROPHIC NGF AND BDNF
Noteworthy, (i) pancreatic beta cells secrete NGF and ex-
press its receptor, tyrosine-kinase A (TrkA), these findings 
being implicated in the pathogenesis of diabetes mellitus 
(29-32), and (ii) systemic and/or local levels of the major 
metabotrophins, NGF and BDNF, are altered (reduced or, 
probably, compensatory elevated) in the major CMD (coro-
nary atherosclerosis, obesity, diabetes, metabolic syndrome) 
(33-42), including acute coronary syndromes (43), and (iii) 
administration of BDNF improves both energy and glucose 
homeostasis (44,45). Metabotrophic effects of NGF and 
BDNF are summarized in Table 3.
CONCLUSION
The discussed findings may implicate the metabotrophic ex-
pression of NGF-ome in the pathogenesis of cardiometabolic 
and neurodegenerative diseases. This hypothesis may open 
new approaches in the search of exogenous metabotrophic 
factors, such as (i) small molecules boosting secretory and/
or signaling pathways of both NGF and BDNF (8,18,19), (ii) 
incretin mimetics and receptor agonists, because the insuli-
notropic hormone glucagon-like peptide-1 (GLP-1) and ex-
endin-4, a GLP-1 receptor agonist, exert both neurotrophic 
and metabotrophic effects (46), and (iii) agents interfering 
with vascular endothelium growth factor (28).
The present challenge is therefore to learn more about the 
metabotrophic potential of human NGF-ome in the patho-
genesis and therapy of cardiometabolic and neurodegenera-
tive diseases.
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